Oncologic Thermoradiotherapy: Need for Evidence, Harmonisation, and Innovation

• Інші автори: Bodis, Stephan (Редактор), Ghadjar, Pirus (Редактор), Van Rhoon, Gerard C. (Редактор)
• Формат: Електронний ресурс Частина з книги
• Мова: Англійська
• Опубліковано: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
• Предмети: Medicine; Oncology; perfusion estimation; temperature monitoring; conductivity reconstruction; systems medicine; immune system in silico; perceptron; antigen pattern; danger signal; fractionation; immune response; head and neck cancer; hyperthermia; reirradiation; treatment outcome; hyperthermia treatment planning; adaptive planning; temperature optimization; low-middle-income group countries; cancer; radiotherapy; chemotherapy; recurrent breast cancers; cervical cancer; head and neck cancers; cost-effective; meta-analysis; intensity-modulated radiotherapy; prostate cancer; thermal dose; thermometric parameters; preclinical data; clinical evidence; modulated electro-hyperthermia; abscopal effect; locally advanced cervical cancer; resource-constrained setting; radiosensitiser; rectal cancer; chemoradiotherapy; tumour control; loco-regional hyperthermia; oncology; cellular selection; bioelectromagnetics; complexity; immune-effects; moderate hyperthermia; deep hyperthermia; radiative hyperthermia; patterns of care; reimbursement; regional hyperthermia; neoadjuvant chemoradiation; survival; induced; brachytherapy; prostatic neoplasms; interstitial hyperthermia; treatment plan optimization; prostate; thermoradiotherapy; linear quadratic model; biological modeling; thermal dosimetry; hypoxia; radiation therapy; reoxygenation; perfusion; oxygen consumption rate; local tumor control; biomarker; immune phenotype; hyperthermia treatment sequence; breast cancer; immune checkpoint molecules; dendritic cell activation; n/a
• Онлайн доступ: DOAB: download the publication; DOAB: description of the publication

The road of acceptance of oncologic thermotherapy/hyperthermia as a synergistic modality in combination with standard oncologic therapies is still bumpy. This is partially due to the lack of level I evidence from international, multicentric, randomized clinical trials including large patient numbers...